Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13138903 | 0.88 | NOS2 (0.47) | NOS2HRH2AKT2KCNH2ACACB | |
| SCHEMBL24866428 | 0.79 | AKT2 (0.44) | NOS2HRH2AKT2KCNH2LMNA | |
| SCHEMBL21263656 | 0.76 | NOS2 (0.44) | NOS2AKT2KCNH2ACACBLMNA | |
| SCHEMBL458851 | 0.76 | TDP1 (0.44) | NOS2AKT2LMNA | |
| SCHEMBL22102496 | 0.76 | NOS2 (0.44) | NOS2HRH2AKT2KCNH2ACACB | |
| SCHEMBL5960562 | 0.75 | — | — | |
| SCHEMBL20539012 | 0.74 | PTGS2 (0.47) | LMNA | |
| SCHEMBL2541661 | 0.74 | PTGS2 (0.47) | LMNA | |
| SCHEMBL28089816 | 0.74 | NOS2 (0.39) | NOS2HRH2AKT2KCNH2ACACB | |
| SCHEMBL26999527 | 0.74 | PTGS2 (0.47) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208032-B2 | Benzamide and nicotinamide compounds and methods of using same | ONCOTARTIS INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20190031658-A1 | BENZAMIDE AND NICOTINAMIDE COMPOUNDS AND METHODS OF USING SAME | ONCOTARTIS INC. | 2019-01-31 | — | — | US | disclosed |
| WO-2015100322-A1 | BENZAMIDE AND NICOTINAMIDE COMPOUNDS AND METHODS OF USING SAME | ONCOTARTIS, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208032-B2 | Benzamide and nicotinamide compounds and methods of using same | NAMPT, NNT, NADK | NOS2 1956/4885HRH2 768/4885AKT2 1555/4885 |
| US-20190031658-A1 | BENZAMIDE AND NICOTINAMIDE COMPOUNDS AND METHODS OF USING SAME | NNT, NAMPT, NNMT | NOS2 1223/4885HRH2 1032/4885AKT2 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.